Type 1 Hemochromatosis: A Review of the History, Inheritance and Treatment of Iron Overload Disorder

Authors

  • Elizabeth Pyle Spaulding High School
  • Valerie Morneault Spaulding High School

DOI:

https://doi.org/10.47611/jsrhs.v12i1.4004

Keywords:

type 1 hemochromatosis, history, inheritance, treatment, iron overload disorder

Abstract

Hereditary hemochromatosis (also known as type 1 hemochromatosis, iron overload disorder, or the Celtic Curse) is a genetic disorder characterized by an autosomal recessive inheritance pattern. This review project focused on gathering comprehensive data about the history, causes, inheritance, diagnosis, and treatment of iron overload disorder. Through such research, it was discovered that type 1 hemochromatosis may occur due to one of two nucleotide sequence changes (either the C282Y mutation or the H63D mutation) in the HFE gene, which codes for the construction of the homeostatic iron regulator protein and regulates production of the hormone hepcidin. As a result of these mutations, individuals affected by hemochromatosis have elevated iron levels and excess deposits of iron in tissues and organs. Such deposits may cause a variety of symptoms and complications, including fatigue, skin discoloration, heart failure, cirrhosis, liver cancer, and diabetes. Hemochromatosis is one of the most common genetic disorders in the world, affecting one in every three hundred individuals. The majority of hemochromatosis patients are of northern European descent. Currently, there is no cure for type 1 hemochromatosis; however, the primary treatment method for this disorder is phlebotomy. Due to the widespread prevalence of the disorder, researchers continue to explore experimental treatment methods, including gene therapy and iron chelation therapy.

Downloads

Download data is not yet available.

References or Bibliography

All About Hemochromatosis. (n.d.). Punnett squares/probability. Hemochromatosis. Retrieved November 18, 2021,

from http://allabouthemochromatosis.weebly.com/punnett-squaresprobability.html

Alturkistani, H. A., Tashkandi, F. M., & Mohammedsaleh, Z. M. (2016). Histological stains: A literature review and

case study. Global Journal of Health Science, 8(3), 72–79. https://doi.org/10.5539/gjhs.v8n3p72

American Diabetes Association. (2020). 7. Diabetes technology: Standards of medical care in diabetes—2020.

Diabetes Care, 43 (Supplement 1), S77–S88. https://doi.org/10.2337/dc20-S007

Anderson, G. J., & Bardou-Jacquet, E. (2021). Revisiting hemochromatosis: Genetic vs . phenotypic manifestations.

Annals of Translational Medicine, 9(8), 731–731. https://doi.org/10.21037/atm-20-5512

Bacon, B.R., & Kwiatkowski, J.L. (2022, July 22). Patient Education: Hereditary Hemochromatosis (Beyond the

Basics). UpToDate. https://www.uptodate.com/contents/hereditary-hemochromatosis-beyond-the-basics/print

Brody, L. (2022, October 28). Missense mutation. National Human Genome Research Institute.

https://www.genome.gov/genetics-glossary/Missense-Mutation

Canadian Hemochromatosis Society. (n.d.). Diagnosis & testing. Canadian Hemochromatosis Society.

https://www.toomuchiron.ca/hemochromatosis/diagnosis-testing/

Centers for Disease Control and Prevention. (2020, July 20). Hereditary hemochromatosis | CDC.

https://www.cdc.gov/genomics/disease/hemochromatosis.htm

Duchini, A., Sfeir, H., & Klachko, D. (2017, April 3). Hemochromatosis: Practice essentials, background,

pathophysiology. Medscape. https://emedicine.medscape.com/article/177216-overview#a6

Ezquer, F., Nunez, M., Rojas, A., Asenjo, J., & Israel, Y. (2006). Hereditary hemochromatosis: An opportunity for

gene therapy. Scielo.Cl. https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602006000100014

The Free Dictionary. (2012). Victor C Hanot. The Free Dictionary By Farlex. Retrieved October 28, 2022, from

https://medical-dictionary.thefreedictionary.com/Victor+C+Hanot

Gene Cards. (2022, August 30). HFE Gene-Homeostatic Iron Regulator. Gene Cards The Human Gene Database.

https://www.genecards.org/cgi-bin/carddisp.pl?gene=HFE

Health Grades. (2020, February 20). The “irish health curse”: 5 fast facts about hemochromatosis. Healthgrades.

https://www.healthgrades.com/right-care/blood-conditions/the-irish-health-curse-5-fast-facts-about-hemochromatosi

s

International Diabetes Federation. (2022, July 7). What is diabetes. International Diabetes Federation. https://www.idf.org/aboutdiabetes/what-is-diabetes.html

Lewis, E. (2016, August 1). Type 1 hereditary hemochromatosis & hfe gene | Hemochromatosis

Help. https://hemochromatosishelp.com/hemochromatosis-gene/

Marks, J. (2021, June 3). Medical Definition of Compound heterozygote. MedicineNet. Retrieved October

, 2022, from https://www.medicinenet.com/compound_heterozygote/definition.htm

Mayo Clinic Staff. (2020, December 30). Hemochromatosis—Diagnosis and treatment—Mayo Clinic. Retrieved

November 18, 2021, from

https://www.mayoclinic.org/diseases-conditions/hemochromatosis/diagnosis-treatment/drc-20351448

Mayo Clinic Staff. (2020, December 30). Hemochromatosis—Symptoms and causes—Mayo Clinic. Retrieved

November 18, 2021, from

https://www.mayoclinic.org/diseases-conditions/hemochromatosis/symptoms-causes/syc-20351443

Medline Plus Genetics. (2019, February 1). Hereditary hemochromatosis. MedlinePlus Genetics. Retrieved

November 18, 2021, from https://medlineplus.gov/genetics/condition/hereditary-hemochromatosis/

Medline Plus Genetics. (2019, February 1). Hfe gene. MedlinePlus Genetics. Retrieved November 18, 2021, from

https://medlineplus.gov/genetics/gene/hfe/

Medline Plus Genetics. (2022, February 28). What is gene therapy?. MedlinePlus Genetics.

https://medlineplus.gov/genetics/understanding/therapy/genetherapy/

Miller, E. J., & Lappin, S. L. (2022, September 14). Physiology, cellular receptor. StatPearls. http://www.ncbi.nlm.nih.gov/books/NBK554403/

Morganette, L. (2017, November 2). Fast facts about hemochromatosis aka iron overload. Patient Worthy.

https://patientworthy.com/2017/11/02/hemochromatosis-iron-overload-facts/

National Health Service. (2018, October 3). Haemochromatosis—Treatment. NHS.

https://www.nhs.uk/conditions/haemochromatosis/treatment/

National Library of Medicine. (1998). Hereditary hemochromatosis. National Center for Biotechnology Information

(US). https://www.ncbi.nlm.nih.gov/books/NBK22223/

Ogun, A. S., & Adeyinka, A. (2022, March 9). Biochemistry, transferrin. StatPearls.

http://www.ncbi.nlm.nih.gov/books/NBK532928/

Online Etymology Dictionary. (2012, December 31). -Osis | meaning of suffix -osis. Etymonline. Retrieved October 28, 2022, from https://www.etymonline.com/word/-osis

Rhee, J.-W., Yi, H., Thomas, D., Sallam, K., Liao, R., & Wu, J. C. (2020, July 14). Modeling Secondary

Iron Overload Cardiomyopathy with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Cell Reports.

https://www.cell.com/cell-reports/pdf/S2211-1247(20)30867-6.pdf

Sapp, J. (2022, May 10). First degree relative. National Human Genome Research Institute.

https://www.genome.gov/genetics-glossary/First-Degree-Relative

Scitable. (2014). Principle of independent assortment. Learn Science at Scitable. https://www.nature.com/scitable/definition/principle-of-independent-assortment-law-of-independent-302/

Ulvik, R. J. (2016). Hereditary haemochromatosis through 150 years. Tidsskrift Den Norske Legeforening.

https://doi.org/10.4045/tidsskr.15.1003

White, T. (2020, September 11). Researchers find potential cure for deadly iron-overload disease. News Center.

Retrieved November 18, 2021, from

http://med.stanford.edu/news/all-news/2020/09/researchers-find-potential-cure-for-deadly-iron-overload-disease.htm

l

Published

02-28-2023

How to Cite

Pyle, E., & Morneault, V. (2023). Type 1 Hemochromatosis: A Review of the History, Inheritance and Treatment of Iron Overload Disorder. Journal of Student Research, 12(1). https://doi.org/10.47611/jsrhs.v12i1.4004

Issue

Section

HS Review Articles